Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 research at MORU

Summary of the COVID research at MORU

COPCOV trial


COPCOV is a global study examining the impact of chloroquine / hydroxychloroquine in preventing COVID-19, COPCOV ended recruitment in December 2021 with 4,646 participants enrolled from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Niger, Pakistan, Thailand, the UK and Zambia. Preliminary study results are expected within Q2 2022.

SEBCOV study


SEBCOV aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing, travel restrictions and other for the COVID-19 pandemic.